Liberum acts as Joint Bookrunner on a £27.5m fundraising for Sensyne Health Plc

The fundraising will enable Sensyne to capitalise on the expanding number and range of commercial opportunities, deliver economies of scale and accelerate future revenue growth. The Company has also entered into an agreement for an exclusive strategic collaboration with Phesi Inc., a US-based specialist clinical trials data company, which will provide Sensyne with the benefit of c.13.5 million international patient records from c.320,000 clinical trials and the ability to market an enhanced offering to the pharmaceutical and biotechnology industry.

The net proceeds of the Placing, Direct Subscription and Open Offer are to be utilised to industrialise and scale the Sensyne data analytics capability and build SENSIGHT™, a pharmaceutical R&D platform, to enter into an exclusive strategic collaboration with Phesi, including an equity investment in Phesi, to further develop the Company’s SENSE™ clinical algorithm engine and to strengthen the Company’s balance sheet.

Liberum have been Joint Broker to Sensyne Health Plc since October 2019. Peel Hunt acted as Nomad and Joint Bookrunner alongside Liberum.

Liberum Team

Investment Banking – Bidhi Bhoma, Euan Brown, William Hall, Nikhil Varghese, Anthony Schia

Sales – Sebastian Fernandez, Julian Collet, Jamie Vickers, Oliver Baxendale, Alistair Smallwood

Research – Graham Doyle

Legal – Rebecca Gordon, Alice Foster

CIR – Georgina Wood, Chris Cooper

Settlements – Mark Proctor, Rob Simpson